At the same time, through targeted drug sensitivity analysis, we found that the expression of ZNF529-AS1 was negatively correlated with sensitivity to multiple targeted drugs, indicating that ZNF529-AS1 may be a potential therapeutic target for HCC. Here, ZNF529 is linked to hepatocellular carcinoma.